Other Consolidated Financial Statement Detail (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Long-term employee compensation and benefits	$ 178,100,000		$ 178,100,000
Long-term taxes payable	187,700,000		187,700,000
Other Income (Expense), Net
Interest income	3,600,000	1,500,000	8,700,000	6,700,000
Interest expense	(7,400,000)	(6,600,000)	(22,100,000)	(25,500,000)
Impairment of investments	0	0	0	(1,700,000)
Gain (loss) on sales of investments, net	(3,100,000)	3,900,000	13,500,000	14,000,000
Foreign exchange gains (losses), net	(4,800,000)	(3,100,000)	(9,500,000)	(11,000,000)
Other, net	(4,600,000)	(300,000)	(7,600,000)	(12,000,000)
Total other income (expense), net	(16,290,000)	(4,640,000)	(17,030,000)	(29,525,000)
Accrued Expenses and Other
Revenue-related rebates	448,700,000		448,700,000		416,300,000
Employee compensation and benefits	323,300,000		323,300,000		343,400,000
Current portion of contingent consideration obligations	219,300,000		219,300,000		29,000,000
Royalties and licensing fees	173,000,000		173,000,000		160,700,000
Deferred revenue	110,000,000		110,000,000		172,700,000
Clinical development expenses	61,100,000		61,100,000		55,200,000
Collaboration expenses	31,000,000		31,000,000		18,700,000
Construction in progress accrual	21,100,000		21,100,000		25,000,000
Other	276,200,000		276,200,000		285,600,000
Total accrued expenses and other	1,544,160,000		1,544,160,000		1,355,187,000
Component of accrued expenses and other
Accrued Expenses and Other
Revenue-related rebates	$ 329,200,000		$ 329,200,000		$ 264,900,000